Lik Lik - Academia.edu (original) (raw)

Papers by Lik Lik

Research paper thumbnail of Profile for Datagram Congestion Control Protocol (DCCP) Congestion Control ID 2: TCP-lik eC ongestion Control

Research paper thumbnail of Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation

Journal of Medical Virology, 2002

This study aimed to investigate the factors associated with viral breakthrough among liver transp... more This study aimed to investigate the factors associated with viral breakthrough among liver transplant recipients who receive lamivudine monoprophylaxis. Consecutive patients receiving liver transplantation for HBV-related liver disease from June 1999 to October 2000 were studied. All patients received lamivudine 100 mg daily pre- and post-transplant. Serum samples were collected before lamivudine treatment, before liver transplantation, and then every 3–6 months after liver transplantation. Lamivudine-resistant mutations at the YMDD motif of HBV P gene were detected by direct sequencing and HBV DNA was quantified by real-time polymerase chain reaction (PCR). Ten patients, 7 males and 3 females, aged 50.5 ± 7.9 years, were studied. Three patients had fulminant hepatitis and 7 patients had end-stage cirrhosis before liver transplantation. Lamivudine was started at 4.5 (range 0–40) weeks before liver transplantation. The median post-transplant follow-up was 16 (range 12–23) months. Four patients developed YMDD mutations 10.5 (0–16) months after transplantation with relapse of viraemia (median 1,294, range 51–3,135 MEq/ml). All patients who developed YMDD mutants had end-stage liver cirrhosis, and HBV DNA were detectable on the day of liver transplantation (median 0.62, range 0.086–1.63 MEq/ml). On the contrary, all 3 patients transplanted for fulminant hepatitis did not have YMDD mutation. Among the 3 end-stage cirrhotic patients who had negative HBV DNA before liver transplantation, none developed YMDD mutation. In conclusion, patients transplanted for fulminant hepatitis B and cirrhotic patients in whom HBV DNA could be rendered PCR negative before liver transplantation are unlikely to develop YMDD mutation on lamivudine monoprophylaxis. J. Med. Virol. 68:182–187, 2002. © 2002 Wiley-Liss, Inc.

Research paper thumbnail of Forming ultracold LiK molecules from LiK mixtures

We present a theoretical study of scattering properties of ultracold Li + K in an external magnet... more We present a theoretical study of scattering properties of ultracold Li + K in an external magnetic field. Based on the isotopes involved, Li-K mixtures can have a fermi-fermi, fermi-bose or bose-bose symmetry. We use the best available molecular potentials adjusted to reproduce recent measurements of Feshbach resonances in a ^6Li-^40K mixtureootnotetextE.Wille et.al. PRL 100, 053201 (2008) to accurately predict the positions of Feshbach resonances and other scattering properties in remaining isotopic mixtures. The effect of higher partial waves in those cases is discussed. We suggest a scheme for photoassociative formation of ultracold LiK molecules in their lowest ro-vibrational levels in the molecular ground state.

Research paper thumbnail of A Computational Model of Trust and Reputation for E-businesses

Google, Inc. (search). ...

Research paper thumbnail of Palm Diesel: Green and Renewable Fuel from

Research paper thumbnail of Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial

Lancet, 2007

Background Guidelines on pain management recommend that patients at risk of ulcers receive either... more Background Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a non-steroidal anti-infl ammatory drug (NSAID) with a proton-pump inhibitor (PPI). These two treatments have similar eff ectiveness, but they are insuffi cient for protection of patients at very high risk for ulcer bleeding. We aimed to test the hypothesis that in patients with previous ulcer bleeding induced by non-selective NSAIDs, combined treatment with the COX 2 inhibitor celecoxib and the PPI esomeprazole would be better than celecoxib alone for prevention of recurrent ulcer bleeding.

Research paper thumbnail of 7374 Case study T5 FINAL NO MARKS

EC Harris was right at the heart of successfully delivering this new £4.3 billion programme. Work... more EC Harris was right at the heart of successfully delivering this new £4.3 billion programme. Working closely with BAA and its suppliers across all 16 interconnecting projects, we played an important role in delivering T5 on time and on budget.

Research paper thumbnail of Profile for Datagram Congestion Control Protocol (DCCP) Congestion Control ID 2: TCP-lik eC ongestion Control

Research paper thumbnail of Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation

Journal of Medical Virology, 2002

This study aimed to investigate the factors associated with viral breakthrough among liver transp... more This study aimed to investigate the factors associated with viral breakthrough among liver transplant recipients who receive lamivudine monoprophylaxis. Consecutive patients receiving liver transplantation for HBV-related liver disease from June 1999 to October 2000 were studied. All patients received lamivudine 100 mg daily pre- and post-transplant. Serum samples were collected before lamivudine treatment, before liver transplantation, and then every 3–6 months after liver transplantation. Lamivudine-resistant mutations at the YMDD motif of HBV P gene were detected by direct sequencing and HBV DNA was quantified by real-time polymerase chain reaction (PCR). Ten patients, 7 males and 3 females, aged 50.5 ± 7.9 years, were studied. Three patients had fulminant hepatitis and 7 patients had end-stage cirrhosis before liver transplantation. Lamivudine was started at 4.5 (range 0–40) weeks before liver transplantation. The median post-transplant follow-up was 16 (range 12–23) months. Four patients developed YMDD mutations 10.5 (0–16) months after transplantation with relapse of viraemia (median 1,294, range 51–3,135 MEq/ml). All patients who developed YMDD mutants had end-stage liver cirrhosis, and HBV DNA were detectable on the day of liver transplantation (median 0.62, range 0.086–1.63 MEq/ml). On the contrary, all 3 patients transplanted for fulminant hepatitis did not have YMDD mutation. Among the 3 end-stage cirrhotic patients who had negative HBV DNA before liver transplantation, none developed YMDD mutation. In conclusion, patients transplanted for fulminant hepatitis B and cirrhotic patients in whom HBV DNA could be rendered PCR negative before liver transplantation are unlikely to develop YMDD mutation on lamivudine monoprophylaxis. J. Med. Virol. 68:182–187, 2002. © 2002 Wiley-Liss, Inc.

Research paper thumbnail of Forming ultracold LiK molecules from LiK mixtures

We present a theoretical study of scattering properties of ultracold Li + K in an external magnet... more We present a theoretical study of scattering properties of ultracold Li + K in an external magnetic field. Based on the isotopes involved, Li-K mixtures can have a fermi-fermi, fermi-bose or bose-bose symmetry. We use the best available molecular potentials adjusted to reproduce recent measurements of Feshbach resonances in a ^6Li-^40K mixtureootnotetextE.Wille et.al. PRL 100, 053201 (2008) to accurately predict the positions of Feshbach resonances and other scattering properties in remaining isotopic mixtures. The effect of higher partial waves in those cases is discussed. We suggest a scheme for photoassociative formation of ultracold LiK molecules in their lowest ro-vibrational levels in the molecular ground state.

Research paper thumbnail of A Computational Model of Trust and Reputation for E-businesses

Google, Inc. (search). ...

Research paper thumbnail of Palm Diesel: Green and Renewable Fuel from

Research paper thumbnail of Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial

Lancet, 2007

Background Guidelines on pain management recommend that patients at risk of ulcers receive either... more Background Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a non-steroidal anti-infl ammatory drug (NSAID) with a proton-pump inhibitor (PPI). These two treatments have similar eff ectiveness, but they are insuffi cient for protection of patients at very high risk for ulcer bleeding. We aimed to test the hypothesis that in patients with previous ulcer bleeding induced by non-selective NSAIDs, combined treatment with the COX 2 inhibitor celecoxib and the PPI esomeprazole would be better than celecoxib alone for prevention of recurrent ulcer bleeding.

Research paper thumbnail of 7374 Case study T5 FINAL NO MARKS

EC Harris was right at the heart of successfully delivering this new £4.3 billion programme. Work... more EC Harris was right at the heart of successfully delivering this new £4.3 billion programme. Working closely with BAA and its suppliers across all 16 interconnecting projects, we played an important role in delivering T5 on time and on budget.